215 related articles for article (PubMed ID: 10926437)
21. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
[TBL] [Abstract][Full Text] [Related]
22. Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.
de Vries R; Daenen S; Tolley K; Glasmacher A; Prentice A; Howells S; Christopherson H; de Jong-van den Berg LT; Postma MJ
Pharmacoeconomics; 2008; 26(1):75-90. PubMed ID: 18088160
[TBL] [Abstract][Full Text] [Related]
23. Antifungal treatment in patients with cancer.
Viscoli C; Castagnola E; Machetti M
J Intern Med Suppl; 1997; 740():89-94. PubMed ID: 9350188
[TBL] [Abstract][Full Text] [Related]
24. Therapy of deep fungal infection in haematological malignancy. Working Party of the British Society for Antimicrobial Chemotherapy.
J Antimicrob Chemother; 1997 Dec; 40(6):779-88. PubMed ID: 9462428
[TBL] [Abstract][Full Text] [Related]
25. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
[TBL] [Abstract][Full Text] [Related]
26. Role of itraconazole in haematology/oncology.
Pandya NA; Atra AA; Riley U; Pinkerton CR
Arch Dis Child; 2003 Mar; 88(3):258-60. PubMed ID: 12598396
[TBL] [Abstract][Full Text] [Related]
27. EPICO 3.0. Empirical antifungal therapy in critically-ill hematology patients.
Llinares P; Ruiz I; Zaragoza R; Ferrer R; Rodríguez AH; Maseda E; Grau S;
Rev Iberoam Micol; 2016; 33(4):206-215. PubMed ID: 27751781
[TBL] [Abstract][Full Text] [Related]
28. Oral antifungals as prophylaxis in haematological malignancy.
Prentice AG; Donnelly P
Blood Rev; 2001 Mar; 15(1):1-8. PubMed ID: 11333134
[TBL] [Abstract][Full Text] [Related]
29. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole.
Glasmacher A; Hahn C; Leutner C; Molitor E; Wardelmann E; Losem C; Sauerbruch T; Marklein G; Schmidt-Wolf IG
Mycoses; 1999; 42(7-8):443-51. PubMed ID: 10546485
[TBL] [Abstract][Full Text] [Related]
30. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias.
Schaffner A; Schaffner M
J Infect Dis; 1995 Oct; 172(4):1035-41. PubMed ID: 7561177
[TBL] [Abstract][Full Text] [Related]
31. Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies.
Böhme A; Just-Nübling G; Bergmann L; Shah PM; Stille W; Hoelzer D
J Antimicrob Chemother; 1996 Dec; 38(6):953-61. PubMed ID: 9023642
[TBL] [Abstract][Full Text] [Related]
32. Are we making progress in antifungal therapy?
Martino P; Girmenia C
Curr Opin Oncol; 1997 Jul; 9(4):314-20. PubMed ID: 9251880
[TBL] [Abstract][Full Text] [Related]
33. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients.
Boogaerts M; Maertens J; van Hoof A; de Bock R; Fillet G; Peetermans M; Selleslag D; Vandercam B; Vandewoude K; Zachée P; De Beule K
J Antimicrob Chemother; 2001 Jul; 48(1):97-103. PubMed ID: 11418517
[TBL] [Abstract][Full Text] [Related]
34. [Economic evaluation of the treatment of systemic fungal infections in immunocompromised patients: the role of itraconazole].
Colombo GL; Morlotti L; Serra G
Recenti Prog Med; 2005 Sep; 96(9):416-23. PubMed ID: 16229321
[TBL] [Abstract][Full Text] [Related]
35. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial.
Boogaerts M; Winston DJ; Bow EJ; Garber G; Reboli AC; Schwarer AP; Novitzky N; Boehme A; Chwetzoff E; De Beule K;
Ann Intern Med; 2001 Sep; 135(6):412-22. PubMed ID: 11560454
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy.
Schuler U; Bammer S; Aulitzky WE; Binder C; Böhme A; Egerer G; Sandherr M; Schwerdtfeger R; Silling G; Wandt H; Glasmacher A; Ehninger G
Onkologie; 2007 Apr; 30(4):185-91. PubMed ID: 17396041
[TBL] [Abstract][Full Text] [Related]
37. Therapy for fungal infections in leukemia.
Segal RE; Minamoto GY
Curr Oncol Rep; 2001 May; 3(3):201-8. PubMed ID: 11296129
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of antifungal prophylaxis with oral itraconazole solution among patients receiving corticosteroids: who should be given prophylaxis?
Iriyama N; Matsukawa Y; Miura K; Inomata H; Hirabayashi Y; Hatta Y; Horikoshi A; Takeuchi J
J Infect Chemother; 2011 Dec; 17(6):744-9. PubMed ID: 21523410
[TBL] [Abstract][Full Text] [Related]
39. Brief report: practicability and safety of amphotericin B deoxycholate as continuous infusion in neutropenic patients with hematological malignancies.
Schulenburg A; Sperr W; Rabitsch W; Knöbl P; Thalhammer F
Leuk Lymphoma; 2005 Aug; 46(8):1163-7. PubMed ID: 16085557
[TBL] [Abstract][Full Text] [Related]
40. Itraconazole in neutropenic patients.
van't Wout JW
Chemotherapy; 1992; 38 Suppl 1():23-6. PubMed ID: 1319311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
